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Diaminopimelic acid (DAP) is a modified lysine amino acid required for cell wall 
synthesis in most bacteria.  This project’s goal was to design a live growth-controllable 
vaccine using a strain of Y. pestis, the causative agent of plague, lacking the DAP gene to 
make its growth dependent on exogenous DAP while allowing host immune responses.  
Y. pestis starvation assays showed that DAP-starved cells cannot revive after 24 hours of 
starvation, and growth curves showed the minimum exogenous DAP concentration 
required per cell.  Mock skin diffusion experiments showed that DAP diffuses through 
“skin”, sustaining and limiting growth to areas of application.  Results suggest that DAP-
dependent Y. pestis can be a live vaccine controlled by DAP application. 
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General Plague Information 
 
Yersinia pestis is a rod-shaped Gram-negative bacterium that causes three forms 
of plague: bubonic, septicemic, and pneumonic (Sebbane et al., 2009). The plague 
originated in rodents from China and spread through infected fleas (Morelli et al., 2010). 
The disease can be transmitted to humans through contact with infected animals, such as 
rodents and pets, or from a bite from their infected fleas. Figure 1 depicts the various 
methods of Yersinia transmission. 
 
Figure 1: Plague Transmission Paths. The solid lines denote typical transmission paths, 
the dashed lines show occasional paths, and the dotted lines show uncommon paths 
(Perry and Fetherston, 1997). 
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Many different strains of Y. pestis have been traced back to the original strain 
from China. Over fifteen strains have been identified in three different branches of a 
phylogenic tree (Morelli et al., 2010). The original strain of Y. pestis actually morphed 
from its close relative Yersinia pseudotuberculosis, which is a gastrointestinal pathogen 
(Parkhill et al., 2001).  
The incubation period for Y. pestis is about three to seven days in humans. 
Depending on how the patient became infected determines which type of plague 
(bubonic, septicemic, or pneumonic) is diagnosed, and each type affects humans 
differently. A bite from an infected flea causes the bubonic plague. It is characterized by 
swollen lymph nodes where the bacteria are doubling quickly. The infected lymph nodes 
can become so large that they become open wounds. The name, bubonic plague, comes 
from the term ―bubo‖ which refers to the enlarged lymph nodes (Fact Sheet: Plague, 
2005). In addition to swollen lymph nodes, other symptoms include headache, fever, 
chills, vomiting, nausea, and diarrhea (Perry and Fetherston, 1997). 
Septicemic plague is similar to bubonic plague in that Y. pestis is introduced 
through the bloodstream. However, bacteremia in septicemic plague does not occur in the 
lymph nodes to form buboes. The cause of this type of infection could be from a flea bite 
or from contact with an infected animal if one has open cuts in the skin (Fact Sheet: 
Plague, 2005). The symptoms of septicemic plague are also similar to those of the 
bubonic plague: fever, chills, headache, and abdominal pains (Perry and Fetherston, 
1997).  
Pneumonic plague can be caused by inhalation of the bacteria from a patient with 
the bubonic plague (from sneezing or coughing) or by aerosolized droplets.  This type is 
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characterized by infection of the lungs, which starts out like the flu but develops into 
pneumonia (Perry and Fetherston, 1997). Its incubation period can be shorter than other 
plagues (about one to three days) and it is extremely virulent, so patients must be kept in 
isolation. This is the only form of the plague which can be transmitted without the 
assistance of animals or fleas (Fact Sheet: Plague, 2005).  Pneumonic plague is the most 
easily spread of the three types, and has a mortality rate of almost 100% (Titball and 
Williamson, 2001).  
Treatment and Prevention 
 
 Because Y. pestis is a bacterium, bubonic plague can be treated fairly well with 
antibiotics if caught early, however it is very difficult to catch septicemic and pneumonic 
forms early because of how rapidly they develop (Titball and Williamson, 2001). The 
typical antibiotic used for treatment is streptomycin, but tetracycline and 
chloramphenicol can be used as well.  Patients are contagious until they have been treated 
for at least two days, and should be quarantined until then. Even with treatment, about 
50% of septicemic patients die (Perry and Fetherston, 1997).   
Antibiotics have also been used in precautionary measures to prevent infection. 
This is atypical and only practiced when people are in close contact with infected patients 
or materials. A live vaccine for the plague has been in use since 1908, EV76. It is an 
attenuated strain of Y. pestis that is pigmentation negative, whereas all virulent strains are 
pigmentation positive (Russell et al., 1995). EV76, however, is not completely safe as a 
1% fatality rate was found in mice studies (Titball and Williamson, 2001). A second type 
of vaccine was a killed formalin-fixed virulent whole cell vaccine, but this type is no 
longer distributed. When in use, the killed vaccine was only given to military personnel 
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and those working with virulent strains. It required three shots over the course of nine 
months and additional booster shots were needed every two years (Perry and Fetherston, 
1997). 
Treatment with antibiotics is mostly effective, only if it is diagnosed at a very 
early stage. Because plague can resemble other gram negative bacterial infections and be 
difficult to diagnose early, it is important to find a more effective vaccine (Perry and 
Fetherston, 1997). Moreover, bioterrorism is an imminent threat because Y. pestis is 
readily available in many laboratories around the world, and it is easily aerosolized to 
cause mass epidemics of the pneumonic form of plague. It has also been found that there 
is a high frequency of antibiotic resistance gene transfer to Y. pestis in the midgut of 
fleas, which poses a huge threat to human health (Hinnebusch et al., 2002).  
Live Vaccines 
 
Vaccination is important for developing immunity to harmful diseases and 
establishing healthy communities. There are different types of vaccines distributed: 
killed, attenuated, sub-unit, and DNA. They all have advantages and disadvantages, and 
some are better for certain diseases.  
Killed vaccines contain a dead version of the normal infectious agent while sub-
unit vaccines contain components of the infectious agent, such as surface proteins. Both 
of these vaccines elicit a sufficient immune response, but booster shots are required for 
complete immunity. Because they are inactivated they can be used for immune-deficient 
patients.  On the other hand, sometimes they can be too weak and not provide an effective 
immunity (Virology, 2010).  
  9 
A new development on DNA vaccines has possible advantages for stability and 
flexibility. DNA vaccines are plasmids that contain a gene encoding an antigen of the 
infectious agent. The DNA sequence can be engineered easily and produced in large 
quantities but there are also severe disadvantages, such as the plasmid integrating into the 
host genome, or the immune system creating anti-DNA antigens (Virology, 2010). 
Because this research is so novel and the exact repercussions are unknown, it is not yet a 
safe method of vaccination.  
Attenuated vaccines are live agents but are mutated to be non-pathogenic. 
Because the vaccine is the actual bacteria or virus, it elicits all parts of the immune 
system and provides the best immunity long term. The immunity is quickly established 
after inoculation, and there is no need for booster shots. Most attenuated vaccines are 
inexpensive to make and transport easily (Emergency Preparedness and Response, 2007).  
Measles, mumps, rubella, and chicken pox are all successful stories of live 
attenuated vaccines.  Once vaccination is complete, patients are completely immune to 
these diseases and do not need booster shots later in life. The major disadvantage to live 
vaccines is that they could mutate themselves and become dangerous. There is also 
concern that the live vaccine could spread to others in contact with the patient and 
accidentally inoculate them as well (Emergency Preparedness and Response, 2007). The 
worst case scenario would be that the vaccine mutated, is now pathogenic, and then 
spreads to others. 
A live vaccine for the plague would provide greater protection against all strains 
of Y. pestis than a sub-unit vaccine which would have limited immunogenic responses. 
One study created an attenuated plague vaccine by mutating the bacterial tyrosine 
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phosphatase, YopH, which is a strong factor in virulence. Y. pestis appears to be avirulent 
when YopH is deleted, therefore it should be a practical live vaccine, but its growth is not 
controllable (Bubeck and Dube, 2007).  
The EV76 attenuated vaccine that is pigmentation negative is not avirulent, and 
therefore it is not permitted for use in humans (Titball and Williamson, 2001). It is 
important to find a bacterial mutation that makes the vaccine avirulent without killing the 
bacterium. Y. pestis can be attenuated by mutating virulence factors or by mutating its 
physical structure. If a virulence factor is removed, then the vaccine will not give the 
patient all the symptoms of plague but the bugs can still infiltrate the body.  Mutating the 
structure of Y. pestis causing it to depend on an outside nutrient would make the 
bacterium avirulent, but its replication would be controllable and it would still elicit a full 
immune response. 
DAP and Live Vaccines 
 
Diaminopimelic acid (DAP) is an optically inactive amino acid in the aspartate 
family, and is an epsilon-carboxy derivative of lysine.  Its main function is as a critical 
component in the cell wall of many bacteria.  In gram negative bacteria such as E. coli 
and Y. pestis, the peptidoglycan layer is composed of linear chains of alternating N-
acetylglucosamine (NAG) and N-acetylmuramic acid (NAM), linked by β-(1,4)-
glycosidic bonds (Meadow et al., 1957).  Each NAM attaches to a 4-5 residue chain of D-
alanine, D-glutamic acid, and meso-diaminopimelic acid.  This composition is thought to 
protect the bacteria from attacks by peptidases.  In bacteria, the decarboxylation of the 
meso isomer αε-diaminopimelic acid forms lysine, a process that is fueled by L-
aminoadipic acid in yeasts and fungi (Bukhari and Taylor, 1970). 
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The asd gene encodes a key enzyme in the biosynthetic synthesis of DAP, β-
semialdehyde dehydrogenase (Galan et al., 1990).  Bacteria lacking this enzyme are 
identified by Δasd.  Lack of the asd gene renders the bacteria unable to synthesize the cell 
wall independently, making the bacteria dependent on an outside source of DAP for cell 
wall replication.  If no outside source of DAP is provided, the cells will lyse due to the 
lack of the cell wall.   
A Δasd mutant of S. flexneri was used in a study by Shata et al. (2000) who 
created an attenuated strain designed to efficiently escape the host endosome, allowing 
for direct access to the cytoplasm of the host cells.  This strain allows for direct targeting 
of the lymphoid tissue in colonic mucosa to elicit muscosal and systemic immune 
responses.  Using this method, a LacZ reporter plasmid was successfully delivered to 
cultured human cells, and expression of the LacZ gene was detected along with an 
observable rise of β-gal-specific antibodies and T-cell proliferation.  The uptake of the 
LacZ gene can be attributed to the lack of DAP to the bacteria – without DAP they could 
not synthesize the cell wall and subsequently lysed, releasing the gene into the lymphoid 
tissue (Shata et al., 2000).  Vaccination approaches using Δasd mutants of Y. pestis have 
not yet been tested. 
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PROJECT PURPOSE 
 
Y. pestis is a highly infectious bacterium that causes three forms of the plague.  
While it is possible to block bubonic plague with a course of antibiotics if caught at the 
earliest stages, this method does not work for pneumonic plague, and would not be 
sufficient if Y. pestis is ever used in an act of bioterrorism where the agent would spread 
human to human via aerosols.  The previous killed vaccine for bubonic plague requires 
three initial inoculations, and boosters every few years thereafter.  A topical live vaccine 
would not only be less painful and easier to administer, but would provide longer lasting, 
stronger immune responses.  Linking the administration of a cell wall-deficient strain to 
the topical application of the missing cell wall component would also contain the 
bacterial replication to the area of application, reducing the risk of peripheral illness 
sometimes experienced with vaccine injections.  Diaminopimelic acid (DAP) is a 
modified lysine amino acid required for cell wall synthesis in most bacteria including Y. 
pestis, so the goal of this project is to test a DAP-deficient strain previously created by 
the Goguen laboratory at UMASS Medical Center to prove it requires exogenous DAP 
for survival, and to determine the minimum DAP concentration required for survival.  In 
addition, the project will test the replication of Δasd mutant Y. pestis on artificial skin 
(20% polyacrylamide gel) to verify the replication is restricted to sites of DAP 
application. 




Y. pestis JG150Δasd and JG150Δasd pML 001 were obtained from Jon Goguen at 
UMASS Medical Center. 
 
Hourly Growth Curves 
In order to determine the amount of DAP required per cell, growth curve 
experiments were performed.  JG150Δasd cells were grown overnight at 37°C in 
TB
+
DAP25 media, and the optical density (OD) was measured.  In order to test the effect 
of different DAP concentrations, these cells were distributed into 25 mL of media 
containing different concentrations of DAP.  In order to quantitatively compare the 
results, each fresh culture was started at an OD of 0.05.  This was calculated from the 
starting OD of 2.06 using the formula cv = cv.  The DAP concentrations used were 2 μM, 
2 nM, 20 pM, 0.2 pM, 2 fM, and 0 DAP as a negative control. The positive control was 2 
μM, as previous experiments performed in our lab had shown this to be a more than a 
sufficient amount of DAP to sustain the mutant strain.  These cultures were incubated at 
37°C, and optical density at λ600 was measured every hour.   
A repeat of this experiment was performed using the same methods described 
above with DAP concentrations of 2 μM, 1 μM, 200 nM, 100 nM, 20 nM, 10 nM, 2 nM, 
and 0 DAP. 
 
 
  14 
Overnight Growth Assays 
After establishing a testable range of DAP concentrations, an overnight growth 
assay was run.  Again, JG150Δasd cells were grown overnight at 37°C in TB+DAP25 
medium.  The cells were washed, and resuspended in fresh media of varying 
concentrations of DAP; including 2 µM, 700 nM, 600 nM, 500 nM, 400 nM, and 0 DAP 
as a negative control.  After an overnight incubation at 37°C, the ODs of these cultures 
were measured and compared. The OD measurements from this experiment were used to 
calculate the amount of DAP each cell requires. 
 
Luminescence Assay 
In preparation for future experiments, growth curve experiments of the mutant 
strain containing an additional luminescence plasmid were performed.  A culture of 
JG150Δasd pML001 cells was grown overnight in TB+DAP25, AMP100 media, washed 
and resuspended into fresh media containing 2 µM DAP, using the same methods and 
concentrations described in the previous section.  A 30 second luminesce measurement 
was taken with the Packard Pico-Lite Luminometer Analyzer for Bio- and Chemi-
Luminescence every hour to track the vitality of the cells in culture over time.  
Concurrently, the optical density of the culture was measured for comparison purposes.  
 
 
DAP Diffusion Through Soft Agar Containing JG150Δasd 
 
JG150Δasd pML001 cells were grown in TB+ DAP25 overnight, and 107 cells 
from the culture were washed with TB+ medium. Soft TB+ agar was melted, aliquoted 
into six 3.5 mL tubes and set in a 42˚C water bath to cool. Five different DAP 
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concentrations (131 µM, 65.5 µM, 2 µM, 700 nM, 600 nM) were spread onto five TB+ 
AMP 100 plates, respectively. No DAP was spread onto a sixth plate as a negative 
control. After the DAP was dried, 100 µL of the washed cells were added to each aliquot 
of soft agar and spread evenly over each plate. Once dry, the plates were incubated at 
37˚C for 7 hours before recording data to allow the cells to reach log phase growth. 
Starting at hour 7, each plate was photographed using the SBIG ST-402 cooled CCD 
camera every hour for 8 hours.  The camera set up is shown in Figure 2. 
 
Figure 2: Set Up of the Light Sensitive SBIG ST-402 Cooled CCD Camera.   
Camera was placed in an incubator in a dark room to ensure  
light detected was from luminescent cells. 
 




JG150Δasd pML001 cells were grown overnight in 25 mL of TB+ DAP AMP100 
medium, then 6 sets of 10
7
 cells were washed in TB+ medium. The cells were added to 
0.5 mL of TB+ top layer soft agar and poured into a small plastic washer. The washer 
was placed on top of a 20% polyacrylamide gel. The gel was made with 30% 
Acrylamide/bis, 1.5 M Tris-HCl (pH7.4), distilled deionized water, 0.05% TEMED (final 
concentration), and 10% APS (0.05% final concentration). On the opposite side of the 
gel, another washer was placed. This washer held various concentrations of DAP (131 
µM, 2 µM, and 0 µM) in 0.5 mL of TB+ top layer soft agar. Each DAP concentration 
was tested on its own gel. The gels were placed in empty plates with damp sterile gauze 
(the complete setup is shown in Figure 3). The plates were grown at 37˚C for 7 hours in 
a desiccator. At the 7
th
 hour the gels were photographed every hour for 8 hours using the 
SBIG ST-402 cooled CCD camera. 
 
Figure 3: Mock Skin Experimental Set Up. 
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Troubleshooting Mock-Skin Experiment 
Since the JG150Δasd pML001 cells did not grow in the mock-skin experiments, 
steps were taken to figure out the reason. The same 20% polyacrylamide gel was 
prepared and the same set up was used, except only 0 µM and 32750 µM DAP 
concentrations were tested. To determine if the cells were not receiving enough oxygen 
for growth, a washer was placed on top of a 20% polyacrylamide gel and 175 µL of TB+ 
soft agar containing 10
7
 cells and 131 µM DAP was added to the washer.  In another 
setup to test oxygen deficiency a 20% polyacrylamide gel was placed between two 
washers. One washer contained 400 µL of TB+ soft agar with 131 µM of DAP. The other 
washer contained 175 µL TB+ soft agar with 10
7
 cells. A final test was performed to 
determine whether the acrylamide was killing the cells. A washer containing TB+ soft 
agar with 10
7
 cells and 131 µM DAP was placed on top of a 20% acrylamide gel. For all 
of the troubleshooting experiments mentioned, the washer-gel setups were placed in 
empty plates with damp sterile gauze. The plates were grown in a desiccator at 37˚C for 7 
hours. Then the gels were photographed using the SBIG ST-402 cooled CCD camera to 




JG150Δasd cells were grown in 25 mL of TB+ DAP25 medium overnight. The 
OD of the culture was measured, the volume containing 300 cells was calculated, and 100 
cells were spread onto three TB+ DAP25 plates. The plates grew over two nights at 37˚C, 
then the colonies were counted. The rest of the culture was split in half and washed 
separately with TB+ medium. One half of the culture was resuspended and grown in 5 
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mL of TB+ DAP25, while the other half was resuspended and grown in 5 mL of TB+ 
medium.  Both cultures were grown at 37˚C over two nights. Again, the OD’s of both 
cultures were measured, calculations for 300 cells from each culture were determined, 
and 100 cells were spread onto three TB+ DAP25 plates. The plates were left on the 
bench for three days to grow, and were then counted for colonies.  
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RESULTS 
 
The goal of this project was to test a DAP-deficient strain Δasd of Y. pestis 
previously created by Jon Goguen to prove it requires exogenous DAP for survival, to 
determine the minimum DAP concentration required for survival, and to test its 
replication on artificial skin (20% acrylamide gel) to verify the replication is restricted to 
sites of DAP application. 
 
Hourly Growth Curves 
 
To verify that the Y. pestis attenuated strain JG150Δasd requires DAP for 
survival, and if so, to determine the minimal concentration of DAP required for survival, 
optical density readings were taken at hour intervals for JG150Δasd cells grown in TB+ 
medium containing various concentrations of DAP: 2 μM, 2 nM, 20 pM, 0.2 pM, 2 fM, 
and 0. An overnight reading was also taken to evaluate the final OD of the cultures.  
From this curve (Figure-4), it is apparent that growth increases for a period of time, then 
begins to plateau due to the exhaustion of the DAP supply.  Because of the large gap in 
final OD readings, the DAP concentrations were altered for subsequent experiments.    
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Figure 4: Hourly growth of JG150Δasd cells in varying concentrations of DAP  
measured by optical density readings at 600 nm, Trial 1. 
 
A repeat growth curve was performed in the same manner as previously 
mentioned, using higher concentrations of DAP (Figure-5).  Concentrations used in this 
trial included 2 μM, 1 μM, 200 nM, 100 nM, 20 nM, 2 nM, and 0.  This growth curve 
further displays the effect of varying concentrations of DAP on JG150Δasd survival.  
Then based on these results, the DAP concentrations were further altered to cover the gap 
observed between 2 μM and the lower concentrations. 
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Figure 5: Hourly growth of JG150Δasd cells in varying concentrations of DAP measured  
by optical density readings at 600 nm, Trial 2. 
 
 
Overnight Growth Assays 
 Due to the very small range of final cell OD readings in the previous set of data, 
the concentration of DAP in the media was greatly increased to a maximum of 2,000 nM 
(2 μM).  JG150Δasd cells were grown in TB+DAP medium containing the following 
concentrations of DAP: 2 μM, 700 nM, 600 nM, 500 nM, 400 nM, and 0 nM.  These 
cultures were incubated overnight, and their final OD readings were measured (Figure 
6).  In this case, there is a very clear increase of growth of the bacteria when the DAP 
concentration is higher.  From this data, we were able to calculate the amount of DAP 
required per cell to sustain growth.  The average DAP required per cell was calculated to 
be 2.29 x 10
-12
 grams. 
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 In order to examine the behavior of JG150Δasd cells containing the luminescence 
plasmid pML001, an hourly luminescence assay was run on a culture of cells grown in 
medium containing 2 μM DAP.  Luminescence readings (in photons) were taken every 
hour and are shown in Figure 7, Panel A.  Optical density was measured concurrently, 
and the growth curve is shown in Figure 7, Panel B.   As the cells ran out of available 
DAP they subsequently died and ceased to glow, causing the luminescence reading to 
decrease over time.  
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Figure 7: A) Luminosity of JG150Δasd pML001 cells in 2 μM TB+DAP AMP100 media over time;  
B) Optical density of JG150Δasd pML001 cells in 2 μM TB+DAP AMP100 media over time 
 
Ability of DAP-Starved Cells to Revive 
 JG150Δasd cells were grown overnight in TB+DAP25 (DAP25 has a 
concentration of 131 µM; high concentration).  One hundred cells were plated onto 
TB+DAP25 media at time zero. The remaining culture was divided in half, one allowed 
to grow again overnight in the presence of DAP, and the other not containing DAP. From 
these cultures, 100 cells were plated onto TB+DAP25 plates to determine if the starved 
cells would be able to grow. As Table 1 shows, the culture initially starved of DAP was 
not able to revive on media containing DAP (no colonies). The cells plated at time zero 
and the cells grown in DAP 25 are controls as they both were able to grow. 
Plate 131 µM DAP 
(Time =0) 
131 µM DAP  
(over two nights) 
No DAP 
(over two nights) 
1 74 67 0 
2 63 88 0 
3 57 83 0 
Average: 64.7 79.3 0 
Table 1: Number of colonies observed at time 0 and after two days growth 
 
 
DAP’s Diffusion Ability 
 
In order to measure the ability of DAP to diffuse through soft agar, JG150Δasd 
pmL001 cells were added to TB+ top layer soft agar and poured onto TB+AMP100 
A B 
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plates with varying DAP concentrations (131 µM, 65.5 µM, 2 µM, 700 nM, 600 nM, and 
0). After 7 hours of growth, pictures of the plates were taken hourly for 8 hours to 
observe growth by luminescence glowing. Figure 8 shows the different concentrations of 
DAP (each has its own panel A-E) and how they affected Y. pestis growth indicated by 
luminescence. All plates with DAP glowed, thus DAP at various concentrations was able 
to diffuse through TB+ top layer soft agar to reach the cells. As earlier experiments 
showed, the cells begin to plateau and die once the available DAP has been used. The 
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Figure 8: DAP Diffusion. Hourly pictures of each plate show areas of growth by glowing (white)  
Y. pestis cells. Each panel in the figure is a series of pictures from a specific DAP concentration.  
Panel A is 0 µM, B is 600 nM, C is 700 nM, D is 2 µM, E is 65.5 µM, and F is 131 µM. 
 
Mock-Skin Experiments 
No luminescence was detected in the mock-skin experiment setup detailed in the 
methods section.  Subsequent experiments were set up to test different aspects of the 
procedure to determine which factor was hindering growth.  Results of these experiments 
indicated that a component of the polyacrylamide gel was toxic to the cells, rendering 
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DISCUSSION 
 
This project explored different aspects of designing a controllable live vaccine for 
plague using a diaminopimelic acid (DAP)-dependent strain of Y. pestis.  Being a novel 
approach to vaccine development, experiments performed in this project established the 
foundation of the potential vaccine.  The first step was to verify that growth of the mutant 
strain was indeed dependent upon DAP, and if so, to determine the minimum amount of 
DAP required by each cell for survival.  This was achieved by performing both hourly 
and overnight growth assays using different concentrations of DAP.  Next, a strain of 
DAP-dependent Y. pestis containing the luminescence plasmid pML001 was tested by 
diffusing different DAP concentrations through soft agar to observe growth using a light 
sensitive camera.  This assay showed that higher concentrations of DAP were needed to 
diffuse through the soft agar to sustain cell growth compared to the liquid media growth 
curves. An attempt at modeling the diffusion of DAP through skin was performed using 
polyacrylamide gel as a skin substitute.  However, growth was not observed in this assay, 
and diagnostic experiments indicated that the polyacrylamide gel was toxic to the cells. 
 Because the polyacrylamide gel is toxic to the cells, an alternative material to 
model skin needs to be used in subsequent experiments.  This would likely be chicken 
skin initially, then progressing to mouse skin. After establishing the amount of DAP 
needed for application to the skin, a lotion will be developed containing an appropriate 
amount of DAP.  Mice will be infected with JG150∆asd pML001 then the DAP lotion 
will be applied to the inoculation site.  Growth of the cells on the skin will be monitored 
using a light sensitive camera.  Ideally, the growth will be contained to the area that 
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received the lotion, preventing the mice from experiencing adverse symptoms previously 
observed in the Y. pestis EV76 live vaccine (Titball & Williamson, 2001). 
 A topical live vaccine for the plague will have many advantages over its 
predecessors. The killed vaccine mentioned in Perry and Fetherston (1997) required three 
injections over nine months, and booster shots were necessary every two years to sustain 
immunity.  A live vaccine would offer a simpler administration as well as a stronger and 
longer lasting immunity.  This would be advantageous if Y. pestis was ever used in an act 
of bioterrorism, as it is highly contagious and easily spread via aerosols. 
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